Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-29

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biological Markers of Response to Treatment in Major Depressive Disorder

NCT00361218

Major Depressive Disorder

COMPLETED PHASE3

Are Two Antidepressants a Good Initial Treatment for Depression?

NCT00296712

Major Depression Dysthymia Depression NOS

COMPLETED PHASE4

Imaging Predictors of Treatment Response in Depression

NCT00367341

Major Depressive Disorder

COMPLETED NA

Treatment of Depression Following Multiple Brain Tests

NCT00296777

Major Depression Dysthymia

COMPLETED PHASE4

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

NCT04388189

Major Depressive Disorder

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

treatment in this study was determined by treatment received in prior study; i.e., those who had received escitalopram then receive escitalopram + bupropion; those initially taking bupropion then receive escitalopram + bupropion

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bupropion added to citalopram

patients who did not remit with citalopram will continue at the same dose and have bupropion added

Group Type ACTIVE_COMPARATOR

bupropion

Intervention Type DRUG

FDA approved drug for treating depression

citalopram

Intervention Type DRUG

FDA approved treatment for depression

citalopram added to bupropion

Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added

Group Type ACTIVE_COMPARATOR

bupropion

Intervention Type DRUG

FDA approved drug for treating depression

citalopram

Intervention Type DRUG

FDA approved treatment for depression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bupropion

FDA approved drug for treating depression

Intervention Type DRUG

citalopram

FDA approved treatment for depression

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Wellbutrin Celexa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* non-remission in Protocol #6559R
* age 18-66
* signs informed consent
* physically healthy

Exclusion Criteria

* bipolar disorder
* history of psychosis
* history of anorexia nervosa or bulimia
* history of seizure disorder, significant brain trauma or other medical reason to suspect increased seizure risk

Minimum Eligible Age

18 Years

Maximum Eligible Age

66 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No